利福昔明
肠易激综合征
医学
肝性脑病
憩室病
疾病
胃肠病学
肠道菌群
小肠细菌生长过度
内科学
重症监护医学
病理生理学
肝硬化
抗生素
免疫学
微生物学
生物
作者
Dan L. Dumitrașcu,И. Г. Бакулин,Annalisa Berzigotti,Marília Cravo,Laura Gombošová,Milan Lukáš,Anna Pietrzak,J.M. Remes-Troche,Manuel Romero–Gómez,Mercedes Amieva Balmori,Tiago Cúrdia Gonçalves,Lamine Hamzaoui,Radovan Juricek,Leticia Moreira,Katarzyna Neubauer,Teodora Surdea‐Blaga,И. Н. Тихонов,Jan Trna,Gianluca Ianiro,Francesca Romana Ponziani,Antonio Gasbarrini
出处
期刊:Journal of Gastrointestinal and Liver Diseases
[Romanian Society of Gastroenterology and Hepatology]
日期:2023-03-31
卷期号:32 (1): 92-109
被引量:7
摘要
Various environmental factors affecting the human microbiota may lead to gut microbial imbalance and to the development of pathologies. Alterations of gut microbiota have been firmly implicated in digestive diseases such as hepatic encephalopathy, irritable bowel syndrome and diverticular disease. However, while these three conditions may all be related to dysfunction of the gut-liver-brain axis, the precise pathophysiology appears to differ somewhat for each. Herein, current knowledge on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease are reviewed, with a special focus on the gut microbiota modulation associated with these disorders during therapy with rifaximin. In general, the evidence for the efficacy of rifaximin in hepatic encephalopathy appears to be well consolidated, although it is less supported for irritable bowel syndrome and diverticular disease. We reviewed current clinical practice for the management of these clinical conditions and underlined the desirability of more real-world studies to fully understand the potential of rifaximin in these clinical situations and obtain even more precise indications for the use of the drug.
科研通智能强力驱动
Strongly Powered by AbleSci AI